000538.SHE · Yunnan Baiyao Group Co.,Ltd

-

Please sign in to comment on 000538.SHE

1 Comment

Admin

4 years ago

Yunnan Baiyao Group Co.,Ltd is currently in a long term downtrend where the price is trading 6.7% below its 200 day moving average.

From a valuation standpoint, the stock is 50.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.8.

Yunnan Baiyao Group Co.,Ltd's total revenue rose by 9.9% to $9B since the same quarter in the previous year.

Its net income has increased by 96.8% to $1B since the same quarter in the previous year.

Finally, its free cash flow fell by 89.2% to $192M since the same quarter in the previous year.

Based on the above factors, Yunnan Baiyao Group Co.,Ltd gets an overall score of 3/5.

Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Exchange	SHE
CurrencyCode	CNY
ISIN	CNE0000008X7

Market Cap	104B
Beta	0.57
PE Ratio	21.77
Target Price	68.4
Dividend Yield	5.6%

ABOUT

Yunnan Baiyao Group Co.,Ltd

Yunnan Baiyao Group Co.,Ltd engages in the pharmaceutical business in China, Southeast Asia, Europe, the United States, Japan, and internationally. It provides health products; drugs; medical devices; traditional Chinese medicine resources; and tea products. The company also supplies and distributes medicines. Yunnan Baiyao Group Co., Ltd. was founded in 1902 and is based in Kunming, China.

000538.SHE · Yunnan Baiyao Group Co.,Ltd

-

Yunnan Baiyao Group Co.,Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Yunnan Baiyao Group Co.,Ltd using a moving average strategy